S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
NYSE:CHE

Chemed (CHE) Stock Price, News & Analysis

$618.51
-0.28 (-0.05%)
(As of 04/12/2024 ET)
Today's Range
$613.24
$618.88
50-Day Range
$571.74
$650.70
52-Week Range
$492.84
$654.62
Volume
72,755 shs
Average Volume
66,520 shs
Market Capitalization
$9.35 billion
P/E Ratio
34.52
Dividend Yield
0.26%
Price Target
$681.00

Chemed MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
10.1% Upside
$681.00 Price Target
Short Interest
Healthy
3.06% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
1.40mentions of Chemed in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$10.18 M Sold Last Quarter
Proj. Earnings Growth
9.28%
From $21.99 to $24.03 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.82 out of 5 stars

Medical Sector

29th out of 925 stocks

Home Health Care Services Industry

2nd out of 8 stocks

CHE stock logo

About Chemed Stock (NYSE:CHE)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

CHE Stock Price History

CHE Stock News Headlines

Buy Alert
Imagine knowing, ahead of time, what the best investments of the year would be… Well, investors no longer need to imagine, guess, or throw darts. See, we’ve uncovered what looks to be a list of THE 10 best opportunities for 2024.
Chemed Corporation (CHE) Rose 13% in Q4
Buy Alert
Imagine knowing, ahead of time, what the best investments of the year would be… Well, investors no longer need to imagine, guess, or throw darts. See, we’ve uncovered what looks to be a list of THE 10 best opportunities for 2024.
CHE Apr 2024 670.000 call
CHE Apr 2024 590.000 put
Chemed Full Year 2023 Earnings: In Line With Expectations
Q4 2023 Chemed Corp Earnings Call
Chemed Q4 2023 Earnings Preview
Chemed: Q4 Earnings Insights
84.3
Chemed Corp. Bottom Line Climbs In Q4, but misses estimates
See More Headlines
Receive CHE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/15 Dividend
2/23/2024
Last Earnings
2/27/2024
Dividend Payable
3/15/2024
Today
4/13/2024
Next Earnings (Confirmed)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Home health care services
Sub-Industry
Health Care Services
CUSIP
16359R10
Employees
15,087
Year Founded
1970

Price Target and Rating

Average Stock Price Target
$681.00
High Stock Price Target
$712.00
Low Stock Price Target
$650.00
Potential Upside/Downside
+10.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$272.51 million
Pretax Margin
15.47%

Debt

Sales & Book Value

Annual Sales
$2.26 billion
Cash Flow
$24.55 per share
Book Value
$73.55 per share

Miscellaneous

Free Float
14,508,000
Market Cap
$9.35 billion
Optionable
Optionable
Beta
0.42

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

CHE Stock Analysis - Frequently Asked Questions

Should I buy or sell Chemed stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CHE shares.
View CHE analyst ratings
or view top-rated stocks.

What is Chemed's stock price target for 2024?

2 brokerages have issued 12 month price objectives for Chemed's stock. Their CHE share price targets range from $650.00 to $712.00. On average, they predict the company's stock price to reach $681.00 in the next twelve months. This suggests a possible upside of 10.1% from the stock's current price.
View analysts price targets for CHE
or view top-rated stocks among Wall Street analysts.

How have CHE shares performed in 2024?

Chemed's stock was trading at $584.75 on January 1st, 2024. Since then, CHE shares have increased by 5.8% and is now trading at $618.51.
View the best growth stocks for 2024 here
.

Are investors shorting Chemed?

Chemed saw a increase in short interest in February. As of February 29th, there was short interest totaling 464,400 shares, an increase of 5.3% from the February 14th total of 441,100 shares. Based on an average daily volume of 78,800 shares, the short-interest ratio is presently 5.9 days. Approximately 3.2% of the company's shares are sold short.
View Chemed's Short Interest
.

When is Chemed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our CHE earnings forecast
.

How can I listen to Chemed's earnings call?

Chemed will be holding an earnings conference call on Thursday, April 25th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Chemed's earnings last quarter?

Chemed Co. (NYSE:CHE) posted its quarterly earnings results on Tuesday, February, 27th. The company reported $6.60 EPS for the quarter, beating the consensus estimate of $6.25 by $0.35. The firm had revenue of $585.90 million for the quarter, compared to the consensus estimate of $586.64 million. Chemed had a trailing twelve-month return on equity of 32.29% and a net margin of 12.03%. The firm's revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.39 EPS.

How often does Chemed pay dividends? What is the dividend yield for Chemed?

Chemed declared a quarterly dividend on Friday, February 16th. Investors of record on Monday, February 26th will be given a dividend of $0.40 per share on Friday, March 15th. This represents a $1.60 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date is Friday, February 23rd.
Read our dividend analysis for CHE
.

Is Chemed a good dividend stock?

Chemed (NYSE:CHE) pays an annual dividend of $1.60 per share and currently has a dividend yield of 0.26%. The company has been increasing its dividend for 15 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 8.93%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CHE will have a dividend payout ratio of 6.66% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CHE.

What guidance has Chemed issued on next quarter's earnings?

Chemed issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of 23.300-23.700 for the period, compared to the consensus EPS estimate of 23.010. The company issued revenue guidance of -.

What is Kevin J. McNamara's approval rating as Chemed's CEO?

1 employees have rated Chemed Chief Executive Officer Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among the company's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Chemed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

Who are Chemed's major shareholders?

Chemed's stock is owned by a variety of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.28%), MJP Associates Inc. ADV (0.01%), BTC Capital Management Inc. (0.01%), Signal Advisors Wealth LLC (0.01%), One Plus One Wealth Management LLC (0.01%) and Ballentine Partners LLC (0.00%). Insiders that own company stock include Brian C Judkins, David Patrick Williams, Donald E Saunders, Kevin J Mcnamara, Michael D Witzeman, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee and Thomas P Rice.
View institutional ownership trends
.

How do I buy shares of Chemed?

Shares of CHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CHE) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners